The longevity and biotechnology industries are focusing on aging in a big way, and it's beginning to show. The fields of Artificial Intelligence (AI) and regenerative medicine are putting their money on combating aging and age-related diseases, and the benefits are likely to be immense. While biotechnology and AI are relatively new concepts, the announcements of funding and collaboration yesterday by and between three companies are bringing those concepts that much closer to the forefront of medicine. Insilico Medicine, a Baltimore-based next-generation AI company specializing in the application of deep learning for target identification, drug discovery and aging research, yesterday announced a collaboration agreement with WuXi AppTec, a leading global contract research outsourcing provider based in Shanghai, China, serving the pharmaceutical, biotech, and medical device industries. "It's a big step not only for Insilico Medicine but for AI and the pharmaceutical industries," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.
After revolutionizing various industry sectors, the introduction of artificial intelligence in healthcare is transforming how we diagnose and treat critical disorders. A team of experts in the Laboratory for Respiratory Diseases at the Catholic University of Leuven, Belgium, trained an AI-based computer algorithm using good quality data. Dr. Marko Topalovic, a postdoctoral researcher in the team, announced that AI was found to be more consistent and accurate in interpreting respiratory test results and in suggesting diagnoses, as compared to lung specialists. Likewise, Artificial Intelligence Research Centre for Neurological Disorders at the Beijing Tiantan Hospital and a research team from the Capital Medical University developed the BioMind AI system, which correctly diagnosed brain tumor in 87% of 225 cases in about 15 minutes, whereas the results of a team of 15 senior doctors displayed only 66% accuracy. The introduction of technologies such as deep learning and artificial intelligence in healthcare can help achieve more efficiency and precision.
In late December last year, Dr. Li Wenliang began warning officials about a novel coronavirus in Wuhan, China, but was silenced by the police before tragically succumbing to the disease two months later. Meanwhile, almost simultaneously, a computer server halfway across the world started issuing worrying alerts of a potential new outbreak. The server runs software by BlueDot, a company based in San Francisco that uses AI to monitor infectious disease outbreaks for signs of early trouble. Not enough people listened to either human expertise or AI. Then cases skyrocketed in Wuhan and spread across the world, and people had to take note.
Machine learning has been an emerging tool for various aspects of infectious diseases including tuberculosis surveillance and detection. However, WHO provided no recommendations on using computer-aided tuberculosis detection software because of the small number of studies, methodological limitations, and limited generalizability of the findings. To quantify the generalizability of the machine-learning model, we developed a Deep Convolutional Neural Network (DCNN) model using a TB-specific CXR dataset of one population (National Library of Medicine Shenzhen No.3 Hospital) and tested it with non-TB-specific CXR dataset of another population (National Institute of Health Clinical Centers). The findings suggested that a supervised deep learning model developed by using the training dataset from one population may not have the same diagnostic performance in another population. Technical specification of CXR images, disease severity distribution, overfitting, and overdiagnosis should be examined before implementation in other settings.
Health care executives from IBM Watson and Athenahealth athn debated that question onstage at Fortune's inaugural Brainstorm Health conference Tuesday. In addition to partnering with Celgene celg to better track negative drug side effects, IBM ibm is applying its cognitive computing AI technology to recommend cancer treatment in rural areas in the U.S., India, and China, where there is a dearth of oncologists, said Deborah DiSanzo, general manager for IBM Watson Health. For example, IBM Watson could read a patient's electronic medical record, analyze imagery of the cancer, and even look at gene sequencing of the tumor to figure out the optimal treatment plan for a particular person, she said. "That is the promise of AI--not that we are going to replace people, not that we're going to replace doctors, but that we really augment the intelligence and help," DiSanzo said. Athenahealth CEO Jonathan Bush, however, disagreed.